MedTrace Logo

The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer

NCT00345059 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2016-01-14

No results posted yet for this study

Summary

The purpose of this study is to compare the overall survival of patients with advanced non small cell lung cancer treated with docetaxel as single therapy versus docetaxel in combination with either gemcitabine or vinorelbine or in combination with capecitabine.

Conditions

Interventions

DRUG

docetaxel

DRUG

vinorelbine

DRUG

gemcitabine

DRUG

capecitabine

Sponsors & Collaborators

  • National Cancer Institute, Naples

    lead OTHER

Principal Investigators

  • Cesare Gridelli, M.D. · S.G. Moscati Hospital, Avellino, Italy; Division of Medical Oncology

  • Francesco Perrone, M.D., Ph.D · National Cancer Institute, Naples Italy; Director Clinical Trials Unit

  • Ciro Gallo, M.D., Ph.D. · Second University of Naples, Italy; Chair Medical Statistics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00345059 on ClinicalTrials.gov